Last reviewed · How we verify
Two cycles of neoadjuvant chemotherapy
Chemotherapy involves the use of drugs to kill rapidly dividing cancer cells.
Chemotherapy involves the use of drugs to kill rapidly dividing cancer cells. Used for Breast cancer, Lung cancer.
At a glance
| Generic name | Two cycles of neoadjuvant chemotherapy |
|---|---|
| Also known as | paclitaxel and carboplatin |
| Sponsor | Seoul National University Hospital |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Neoadjuvant chemotherapy is administered before the main treatment, such as surgery, to reduce the size of the tumor. This approach can make the subsequent treatment more effective.
Approved indications
- Breast cancer
- Lung cancer
Common side effects
- Nausea
- Fatigue
- Hair loss
- Anemia
- Infection
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk (PHASE2)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers (PHASE1, PHASE2)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Angiomammography and Neoadjuvant Chemotherapy (NA)
- Neoadjuvant Pembrolizumab (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: